Alzheimer’s disease (AD) is a neurodegenerative illness that causes tau aggregation and amyloid-beta plaque accumulation in the brain, which gradually impairs memory and cognition. Despite extensive research, current therapeutic options remain limited and often carry significant side effects. This study explores flavonoids, bioactive plant-derived compounds, as potential treatment candidates with multi-target activity against AD. A total of 55 flavonoids, selected based on neuroprotective relevance and retrieved from the PubChem database, were screened for their multi-target potential against AD. A comprehensive approach integrating systems pharmacology (SwissTarget, GeneCards, STRING), network visualization and hub analysis (Cytoscape), enrichment analysis (DAVID, SRplot), correlation validation (GEPIA), drug-likeness and ADMET profiling (SwissADME, pkCSM, ProTox-II), molecular docking (Maestro–Schrödinger), and molecular dynamics simulations (Desmond) was employed to uncover the molecular basis of flavonoids’ neuroprotective effects. Through systems pharmacology, essential AD-related targets were identified, and a protein–protein interaction network was developed, highlighting 32 common targets. Enrichment analysis revealed critical pathways in AD pathogenesis, including MAPK signaling, apoptotic processes, and amyloid precursor protein processing. Computational docking revealed high interaction strengths of flavonoids, specifically morin, luteolin, and genistein, against key AD-associated targets, including acetylcholinesterase, β-site APP cleaving enzyme 1, glycogen synthase kinase-3 beta, and dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). Morin demonstrated the strongest binding affinity with a Glide XP docking score of –9.277 kcal/mol against DYRK1A, outperforming luteolin (–9.256 kcal/mol) and genistein (–9.133 kcal/mol). Molecular simulations further confirmed the stability of the Morin–DYRK1A complex (RMSD <3 Å over 150 ns). These results indicate that flavonoids may exhibit promise as treatment candidates for AD.
Logeshwari B, Jeyabalan S, Veeraraghavan G, Krishnaraj K, Ashok C, Pandiyan DD. Exploring flavonoids as multi-target therapeutic agents in Alzheimer’s disease: Insights from Network Pharmacology, Molecular Docking, and Dynamics. J Appl Pharm Sci. 2025. Article in Press. http://doi.org/10.7324/JAPS.2025.v15.i11.12
1. Aisen PS, Jimenez-Maggiora GA, Rafii MS, Walter S, Raman R. Early-stage Alzheimer disease: getting trial-ready. Nat Rev Neurol. 2022;18(7):389-99. https://doi.org/10.1038/s41582-022-00645-6 | |
2. 2024 Alzheimer's disease facts and figures. Alzheimers Dement. 2024;20(5):3708-821. https://doi.org/10.1002/alz.13809 | |
3. Karimi Tari P, Parsons CG, Collingridge GL, Rammes G. Memantine: updating a rare success story in pro-cognitive therapeutics. Neuropharmacology 2024;244:109737. https://doi.org/10.1016/j.neuropharm.2023.109737 | |
4. Zhang J, Zhang Y, Wang J, Xia Y, Zhang J, Chen L. Recent advances in Alzheimer's disease: mechanisms, clinical trials and new drug development strategies. Signal Transduct Target Ther. 2024;9(1):1-35. https://doi.org/10.1038/s41392-024-01911-3 | |
5. Naik RA, Rajpoot R, Koiri RK, Bhardwaj R, Aldairi AF, Johargy AK, et al. Dietary supplementation and the role of phytochemicals against the Alzheimer's disease: focus on polyphenolic compounds. J Prev Alzheimers Dis. 2025;12(1):100004. https://doi.org/10.1016/j.tjpad.2024.100004 | |
6. Atrahimovich D, Harris R, Eitan R, Cohen M, Khatib S. Galantamine quantity and alkaloid profile in the bulbs of Narcissus tazetta and daffodil cultivars (Amaryllidaceae) grown in Israel. Metabolites 2021;11(3):185. https://doi.org/10.3390/metabo11030185 | |
7. Akaberi M, Baharara H, Amiri MS, Moghadam AT, Sahebkar A, Emami SA. Ginkgo biloba: an updated review on pharmacological, ethnobotanical, and phytochemical studies. Pharmacol Res - Mod Chin Med. 2023;9:100331. https://doi.org/10.1016/j.prmcm.2023.100331 | |
8. Zhang LX, Li CX, Kakar MU, Khan MS, Wu PF, Amir RM, et al. Resveratrol (RV): a pharmacological review and call for further research. Biomed Pharmacother. 2021;143:112164. https://doi.org/10.1016/j.biopha.2021.112164 | |
9. Yadav E, Yadav P, Khan MMU, Singh H, Verma A. Resveratrol: a potential therapeutic natural polyphenol for neurodegenerative diseases associated with mitochondrial dysfunction. Front Pharmacol. 2022;13:922232. https://doi.org/10.3389/fphar.2022.922232 | |
10. Islam MdR, Rauf A, Akash S, Trisha SI, Nasim AH, Akter M, et al. Targeted therapies of curcumin focus on its therapeutic benefits in cancers and human health: molecular signaling pathway-based approaches and future perspectives. Biomed Pharmacother. 2024;170:116034. https://doi.org/10.1016/j.biopha.2023.116034 | |
11. Buzdar J, Shah Q, Khan M, Zaheer A, Shah T, Ataya F, et al. Hepatoprotective effects of olive leaf extract against carbon tetrachloride-induced oxidative stress: in vivo and in-silico insights into the Nrf2-NFκB pathway. J Mol Histol. 2025;56:42. https://doi.org/10.1007/s10735-024-10325-y | |
12. Chen H, Buzdar JA, Riaz R, Fouad D, Ahmed N, Shah QA, et al. Bovine lactoferrin alleviates aflatoxin B1 induced hepatic and renal injury in broilers by mediating Nrf2 signaling pathway. Poult Sci. 2024;103(12):104316. https://doi.org/10.1016/j.psj.2024.104316 | |
13. Minocha T, Birla H, Obaid AA, Rai V, Sushma P, Shivamallu C, et al. Flavonoids as promising neuroprotectants and their therapeutic potential against Alzheimer's disease. Oxid Med Cell Longev. 2022;2022:6038996. https://doi.org/10.1155/2022/6038996 | |
14. Forni C, Facchiano F, Bartoli M, Pieretti S, Facchiano A, D'Arcangelo D, et al. Beneficial role of phytochemicals on oxidative stress and age-related diseases. BioMed Res Int. 2019;2019(1):8748253. https://doi.org/10.1155/2019/8748253 | |
15. Kamatham PT, Shukla R, Khatri DK, Vora LK. Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: breaking the memory barrier. Ageing Res Rev. 2024;101:102481. https://doi.org/10.1016/j.arr.2024.102481 | |
16. Hasibuan PAZ, Simanjuntak Y, Hey-Hawkins E, Lubis MF, Rohani AS, Park MN, et al. Unlocking the potential of flavonoids: natural solutions in the fight against colon cancer. Biomed Pharmacother. 2024;176:116827. https://doi.org/10.1016/j.biopha.2024.116827 | |
17. Hasnat H, Shompa SA, Islam MdM, Alam S, Richi FT, Emon NU, et al. Flavonoids: a treasure house of prospective pharmacological potentials. Heliyon 2024;10(6):e27533. https://doi.org/10.1016/j.heliyon.2024.e27533 | |
18. Bordoloi S, Pathak K, Devi M, Saikia R, Das J, Kashyap VH, et al. Some promising medicinal plants used in Alzheimer's disease: an ethnopharmacological perspective. Discov Appl Sci. 2024;6(5):215. https://doi.org/10.1007/s42452-024-05811-7 | |
19. Gao W, Yang G, Liu X, Hu K, Pan J, Wang X, et al. Network pharmacology and experimental verification to investigate the mechanism of isoliquiritigenin for the treatment of Alzheimer's disease. Sci Rep. 2025;15(1):4379. https://doi.org/10.1038/s41598-025-88542-y | |
20. Zhou X, Yan Z, Wang Y, Ren Q, Liu X, Fang G, et al. Based on network pharmacology and RNA sequencing techniques to explore the molecular mechanism of Huatan Jiangzhuo decoction for treating hyperlipidemia. Evid Based Complement Alternat Med. 2021;2021(1):9863714. https://doi.org/10.1155/2021/9863714 | |
21. Patil N, Dhariwal R, Mohammed A, Wei LS, Jain M. Network pharmacology-based approach to elucidate the pharmacologic mechanisms of natural compounds from Dictyostelium discoideum for Alzheimer's disease treatment. Heliyon 2024;10(8):e28852. https://doi.org/10.1016/j.heliyon.2024.e28852 | |
22. Rasool K, Bhatti A, Satti AM, Paracha RZ, John P. Computational insights into the inhibitory mechanism of type 2 diabetes mellitus by bioactive components of Oryza sativa L. indica (black rice). Front Pharmacol. 2024;15:1457383. https://doi.org/10.3389/fphar.2024.1457383 | |
23. Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51(D1):D638-46. https://doi.org/10.1093/nar/gkac1000 | |
24. Aloliqi AA. Insights into the gene expression profile of classical hodgkin lymphoma: a study towards discovery of novel therapeutic targets. Molecules 2024;29(15):3476. https://doi.org/10.3390/molecules29153476 | |
25. Fan N, Yuan S, Hai Y, Du P, Li J, Kong X, et al. Identifying the potential role of IL-1β in the molecular mechanisms of disc degeneration using gene expression profiling and bioinformatics analysis. J Orthop Surg Hong Kong. 2022;30(1):23094990211068203. https://doi.org/10.1177/23094990211068203 | |
26. Mohanty D, Padhee S, Sahoo C, Jena S, Sahoo A, Chandra Panda P, et al. Integrating network pharmacology and experimental verification to decipher the multitarget pharmacological mechanism of Cinnamomum zeylanicum essential oil in treating inflammation. Heliyon 2024;10(2):e24120. https://doi.org/10.1016/j.heliyon.2024.e24120 | |
27. De Simone A, Tumiatti V, Andrisano V, Milelli A. Glycogen synthase kinase 3β: a new gold rush in anti-Alzheimer's disease multitarget drug discovery? J Med Chem. 2021;64(1):26-41. https://doi.org/10.1021/acs.jmedchem.0c00931 | |
28. Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556-60. https://doi.org/10.1093/nar/gkz430 | |
29. Gnanaraj C, Sekar M, Fuloria S, Swain SS, Gan SH, Chidambaram K, et al. In silico Molecular docking analysis of karanjin against Alzheimer's and Parkinson's diseases as a potential natural lead molecule for new drug design, development and therapy. Molecules 2022;27(9):2834. https://doi.org/10.3390/molecules27092834 | |
30. Aqil F, Munagala R, Jeyabalan J, Vadhanam MV. Bioavailability of phytochemicals and its enhancement by drug delivery systems. Cancer Lett. 2013;334(1):133-41. https://doi.org/10.1016/j.canlet.2013.02.032 | |
31. Kciuk M, Malinowska M, Gieleci?ska A, Sundaraj R, Mujwar S, Zawisza A, et al. Synthesis, computational, and anticancer in vitro investigations of aminobenzylnaphthols derived from 2-naphtol, benzaldehydes, and α-aminoacids via the betti reaction. Molecules 2023;28(20):7230. https://doi.org/10.3390/molecules28207230 | |
32. Coburger I, Hoefgen S, Than ME. The structural biology of the amyloid precursor protein APP - a complex puzzle reveals its multi-domain architecture. Biol Chem. 2014;395(5):485-98. https://doi.org/10.1515/hsz-2013-0280 | |
33. Ugbaja SC, Sanusi ZK, Appiah-Kubi P, Lawal MM, Kumalo HM. Computational modelling of potent β-secretase (BACE1) inhibitors towards Alzheimer's disease treatment. Biophys Chem. 2021;270:106536. https://doi.org/10.1016/j.bpc.2020.106536 | |
34. Balboni B, Tripathi SK, Veronesi M, Russo D, Penna I, Giabbai B, et al. Identification of novel GSK-3β hits using competitive biophysical assays. Int J Mol Sci. 2022;23(7):3856. https://doi.org/10.3390/ijms23073856 | |
35. Islam MT, Aktaruzzaman M, Saif A, Hasan AR, Sourov MMH, Sikdar B, et al. Identification of acetylcholinesterase inhibitors from traditional medicinal plants for Alzheimer's disease using in silico and machine learning approaches. RSC Adv. 2024;14(47):34620-36. https://doi.org/10.1039/D4RA05073H | |
36. Chen JH, Tu HJ, Lin TE, Peng ZX, Wu YW, Yen SC, et al. Discovery of dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors using an artificial intelligence model and their effects on tau and tubulin dynamics. Biomed Pharmacother. 2024;181:117688. https://doi.org/10.1016/j.biopha.2024.117688 | |
37. Samanta P, Mishra SK, Pomin VH, Doerksen RJ. Docking and molecular dynamics simulations clarify binding sites for interactions of novel marine sulfated glycans with SARS-CoV-2 spike glycoprotein. Mol Basel Switz. 2023;28(17):6413. https://doi.org/10.3390/molecules28176413 | |
38. Manandhar S, Sankhe R, Priya K, Hari G, Kumar BH, Mehta CH, et al. Molecular dynamics and structure-based virtual screening and identification of natural compounds as Wnt signaling modulators: possible therapeutics for Alzheimer's disease. Mol Divers. 2022;26(5):2793-811. https://doi.org/10.1007/s11030-022-10395-8 | |
39. Valdez-Gaxiola CA, Rosales-Leycegui F, Gaxiola-Rubio A, Moreno- Ortiz JM, Figuera LE. Early- and late-onset Alzheimer's disease: two sides of the same coin? Diseases 2024;12(6):110. https://doi.org/10.3390/diseases12060110 | |
40. Liu E, Zhang Y, Wang JZ. Updates in Alzheimer's disease: from basic research to diagnosis and therapies. Transl Neurodegener. 2024;13(1):45. https://doi.org/10.1186/s40035-024-00432-x | |
41. Andrew RJ, Fernandez CG, Stanley M, Jiang H, Nguyen P, Rice RC, et al. Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer's disease. Proc Natl Acad Sci U S A. 2017;114(45):E9665-74. https://doi.org/10.1073/pnas.1708568114 | |
42. Azargoonjahromi A. The duality of amyloid-β: its role in normal and Alzheimer's disease states. Mol Brain. 2024;17(1):44. https://doi.org/10.1186/s13041-024-01118-1 | |
43. Basheer N, Smolek T, Hassan I, Liu F, Iqbal K, Zilka N, et al. Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer's disease? From preclinical studies to the clinical trials. Mol Psychiatry. 2023;28(6):2197-214. https://doi.org/10.1038/s41380-023-02113-z | |
44. Fang C, Xu H, Yuan L, Zhu Z, Wang X, Liu Y, et al. Natural compounds for SIRT1-mediated oxidative stress and neuroinflammation in stroke: a potential therapeutic target in the future. Oxid Med Cell Longev. 2022;2022:1949718. https://doi.org/10.1155/2022/1949718 | |
45. Rodrigues B, Ventura E, Moreira P, Resende R, Bicker J, Santos AE, et al. New low-dose curcumin derivative with therapeutic potential in Alzheimer's disease: results from an in vitro and in vivo study in mice. Neurobiol Aging. 2025;147:105-23. https://doi.org/10.1016/j.neurobiolaging.2024.12.005 | |
46. Li C, Liu K, Liu S, Aerqin Q, Wu X. Role of ginkgolides in the inflammatory immune response of neurological diseases: a review of current literatures. Front Syst Neurosci [Internet]. 2020;14:45. https://doi.org/10.3389/fnsys.2020.00045 | |
47. Zhu B, Parsons T, Foley C, Shaw Y, Dunckley T, Hulme C, et al. DYRK1A antagonists rescue degeneration and behavioural deficits of in vivo models based on amyloid-β, Tau and DYRK1A neurotoxicity. Sci Rep. 2022;12:15847. https://doi.org/10.1038/s41598-022-19967-y | |
48. Chatterjee S, Mudher A. Alzheimer's disease and type 2 diabetes: a critical assessment of the shared pathological traits. Front Neurosci. 2018;12:383. https://doi.org/10.3389/fnins.2018.00383 | |
49. Okella H, Okello E, Mtewa AG, Ikiriza H, Kaggwa B, Aber J, et al. ADMET profiling and molecular docking of potential antimicrobial peptides previously isolated from African catfish, Clarias gariepinus. Front Mol Biosci. 2022;9:1039286. https://doi.org/10.3389/fmolb.2022.1039286 | |
50. Alshweiat A, Jaber M, Abuawad A, Athamneh T, Oqal M. Recent insights into nanoformulation delivery systems of flavonoids against glioblastoma. J Drug Deliv Sci Technol. 2024;91:105271. https://doi.org/10.1016/j.jddst.2023.105271 | |
51. Prasanna P, Upadhyay A. Flavonoid-based nanomedicines in Alzheimer's disease therapeutics: promises made, a long way to go. ACS Pharmacol Transl Sci. 2021;4(1):74-95. https://doi.org/10.1021/acsptsci.0c00224 | |
52. Juhairiyah F, de Lange ECM. Understanding drug delivery to the brain using liposome-based strategies: studies that provide mechanistic insights are essential. AAPS J. 2021;23(6):114. https://doi.org/10.1208/s12248-021-00648-z | |
53. Talebi M, Shahbazi K, Dakkali MS, Akbari M, Almasi Ghale R, Hashemi S, et al. Phytosomes: a promising nanocarrier system for enhanced bioavailability and therapeutic efficacy of herbal products. Phytomedicine Plus. 2025;5(2):100779. https://doi.org/10.1016/j.phyplu.2025.100779 | |
54. Salehi B, Calina D, Docea AO, Koirala N, Aryal S, Lombardo D, et al. Curcumin's nanomedicine formulations for therapeutic application in neurological diseases. J Clin Med. 2020;9(2):430. https://doi.org/10.3390/jcm9020430 | |
55. Teixeira MI, Lopes CM, Amaral MH, Costa PC. Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): a current overview of active targeting in brain diseases. Colloids Surf B Biointerfaces. 2023;221:112999. https://doi.org/10.1016/j.colsurfb.2022.112999 | |
Year
Month